ATE378406T1 - Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen - Google Patents

Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen

Info

Publication number
ATE378406T1
ATE378406T1 AT03016150T AT03016150T ATE378406T1 AT E378406 T1 ATE378406 T1 AT E378406T1 AT 03016150 T AT03016150 T AT 03016150T AT 03016150 T AT03016150 T AT 03016150T AT E378406 T1 ATE378406 T1 AT E378406T1
Authority
AT
Austria
Prior art keywords
hla
presented
mage
gene
applications
Prior art date
Application number
AT03016150T
Other languages
English (en)
Inventor
Thierry Boon-Falleur
Der Bruggen Pierre Van
Plaen Etienne De
Christophe Lurquin
Catia Traversari
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,334 external-priority patent/US5405940A/en
Priority claimed from US08/037,230 external-priority patent/US6235525B1/en
Priority claimed from US08/073,103 external-priority patent/US5462871A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE378406T1 publication Critical patent/ATE378406T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AT03016150T 1992-08-31 1993-08-30 Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen ATE378406T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/938,334 US5405940A (en) 1992-08-31 1992-08-31 Isolated nonapeptides derived from MAGE genes and uses thereof
US08/037,230 US6235525B1 (en) 1991-05-23 1993-03-26 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US08/073,103 US5462871A (en) 1992-08-31 1993-06-07 Isolated nucleic acid molecules which encode MAGE derived nonapeptides

Publications (1)

Publication Number Publication Date
ATE378406T1 true ATE378406T1 (de) 2007-11-15

Family

ID=26713936

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03016150T ATE378406T1 (de) 1992-08-31 1993-08-30 Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
AT93920419T ATE280180T1 (de) 1992-08-31 1993-08-30 Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93920419T ATE280180T1 (de) 1992-08-31 1993-08-30 Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen

Country Status (12)

Country Link
US (2) US5695994A (de)
EP (1) EP0658113B1 (de)
JP (1) JP3608788B2 (de)
AT (2) ATE378406T1 (de)
AU (1) AU668772B2 (de)
CA (1) CA2143335C (de)
DE (1) DE69333670T2 (de)
DK (1) DK0658113T3 (de)
ES (1) ES2225824T3 (de)
FI (1) FI950887A0 (de)
PT (1) PT658113E (de)
WO (1) WO1994005304A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US6222012B1 (en) * 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
CA2211448A1 (en) * 1995-03-21 1996-09-26 Ludwig Institute For Cancer Research Rage tumor rejection antigens
EP0873350A4 (de) * 1995-06-29 1999-06-30 Ludwig Inst Cancer Res Isolierte nukleinsäuremoleküle, die den maustumoralstossungs-antigenvorläufer smage-3 kodieren
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
EP1584685B1 (de) 1998-02-05 2011-04-13 GlaxoSmithKline Biologicals SA Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung
PT1282702E (pt) 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
EP2295575A3 (de) 2000-12-04 2011-07-06 Immunotope, Inc. Zytotoxische T-Lymphozyten induzierende Immunogene zur Prävention, Behandlung und Diagnose von Krebs
WO2002068451A2 (en) * 2001-02-26 2002-09-06 Albany Medical College Sperm protein 17 for the diagnosis and treatment of cancer
CA2443968A1 (en) 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer: i
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CA2510238A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Cancer treatment using vaccine and high-dose cytokine
CN103288920B (zh) 2003-01-30 2015-08-12 苏瓦克有限公司 存活蛋白衍生肽及其用途
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
KR101216655B1 (ko) 2003-11-19 2013-01-02 수르벡 에이피에스 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
AR069798A1 (es) 2007-12-20 2010-02-17 Novartis Ag Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
RU2012139182A (ru) 2010-02-22 2014-03-27 Ф. Хоффманн-Ля Рош Аг ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
SI2755997T1 (sl) * 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
JP6059731B2 (ja) 2011-10-28 2017-01-11 ノバルティス アーゲー 新規プリン誘導体および疾患の処置におけるその使用
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
EP3076969B1 (de) 2013-12-06 2021-09-01 Novartis AG Dosierungsschema für einen alpha-isoform-selektiven phosphatidylinositol-3-kinase-hemmer
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CN110573522B (zh) 2017-01-05 2023-09-19 卡尔医学有限公司 SIRPα-41BBL融合蛋白及其使用方法
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
WO2019145509A1 (en) 2018-01-26 2019-08-01 Cambridge Enterprise Limited Peptide exchange protein
EP3814385A4 (de) 2018-07-11 2022-04-06 KAHR Medical Ltd. Sirpalpha-4-1bbl-fusionsproteinvariante und ihre verwendung
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020041662A1 (en) 2018-08-24 2020-02-27 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
BR112022000319A2 (pt) 2019-07-11 2022-03-15 Kahr Medical Ltd Heterodímeros e métodos de uso dos mesmos
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492760A (en) * 1983-04-19 1985-01-08 The Wistar Institute Of Anatomy And Biology HLA D Typing assay
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
JPH03505276A (ja) * 1988-02-05 1991-11-21 ジェンザイム・コーポレーション 再配列された組織プラスミノーゲン活性化因子及びその産生方法
WO1992002543A1 (en) * 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof

Also Published As

Publication number Publication date
ATE280180T1 (de) 2004-11-15
US6379901B1 (en) 2002-04-30
DE69333670D1 (de) 2004-11-25
EP0658113A1 (de) 1995-06-21
AU5096993A (en) 1994-03-29
AU668772B2 (en) 1996-05-16
EP0658113A4 (de) 1997-11-26
FI950887A (fi) 1995-02-27
JPH08500837A (ja) 1996-01-30
EP0658113B1 (de) 2004-10-20
JP3608788B2 (ja) 2005-01-12
DE69333670T2 (de) 2005-03-10
CA2143335C (en) 2000-03-14
ES2225824T3 (es) 2005-03-16
FI950887A0 (fi) 1995-02-27
WO1994005304A1 (en) 1994-03-17
DK0658113T3 (da) 2005-02-14
CA2143335A1 (en) 1994-03-17
PT658113E (pt) 2005-03-31
US5695994A (en) 1997-12-09

Similar Documents

Publication Publication Date Title
ATE378406T1 (de) Vom mage-3-gen en abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
DE69334186D1 (de) Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen
NO950660L (no) Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav
NO955063D0 (no) Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav
ATE258379T1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
HUP0000421A2 (hu) Retrovirális vektorok
CA2159098A1 (en) Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
DE69520959T2 (de) Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
BR9707819A (pt) Imunogenos peptidicos
HUP9904368A2 (hu) Colostrinin és alkalmazása
DE59105609D1 (de) Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Ischämien und deren Folgen.
DE69511399T2 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
UA66753C2 (en) Immunostimulator and method for its production

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties